36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Michael J. Bloch; Ajay J. Kirtane; Michel Azizi; Felix Mahfoud; Jan Basile; Joost Daemen; Manish Saxena; Lisa Thackeray; Maureen McGuire; Lisa Claude; Roland E. Schmieder; Michiel Voskuil; Peter Blankestijn

doi:10.1038/s41440-024-01854-w

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Michael J. Bloch^*, Ajay J. Kirtane, Michel Azizi, Felix Mahfoud, Jan Basile, Joost Daemen, Manish Saxena, Lisa Thackeray, Maureen McGuire, Lisa Claude, Roland E. Schmieder, Michiel Voskuil, Peter Blankestijn,

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)

Original language	English
Pages (from-to)	3467–3472
Number of pages	6
Journal	Hypertension Research
Volume	47
Issue number	12
DOIs	https://doi.org/10.1038/s41440-024-01854-w
Publication status	Published - Dec 2024

Keywords

blood pressure
Hypertension
renal denervation
ultrasound

Access to Document

10.1038/s41440-024-01854-wLicence: CC BY

s41440-024-01854-wFinal published version, 1 MBLicence: CC BY

Cite this

Bloch, M. J., Kirtane, A. J., Azizi, M., Mahfoud, F., Basile, J., Daemen, J., Saxena, M., Thackeray, L., McGuire, M., Claude, L., Schmieder, R. E., Voskuil, M., Blankestijn, P. (2024). 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. Hypertension Research, 47(12), 3467–3472. https://doi.org/10.1038/s41440-024-01854-w

@article{351e466c980440f1b0881fe6f51a7c7e,

title = "36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO",

abstract = "Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)",

keywords = "blood pressure, Hypertension, renal denervation, ultrasound",

author = "Bloch, {Michael J.} and Kirtane, {Ajay J.} and Michel Azizi and Felix Mahfoud and Jan Basile and Joost Daemen and Manish Saxena and Lisa Thackeray and Maureen McGuire and Lisa Claude and Schmieder, {Roland E.} and Patric Kr{\"o}pil and Johannes Stegbauer and Christian Rump and Michael Uder and Christian Ott and Jelena Lucic and Sebastian Ewen and Michael B{\"o}hm and Rommel, {Karl Philipp} and Karl Fengler and Robert H{\"o}llriegel and Philipp Lurz and Cristina Elorz and Marshall, {Andrew John} and Mohamad Faris and Robert Gerber and Richard D{\textquoteright}Souza and Anil Joseph and Sharp, {Andrew S.P.} and James Howard and Shin, {Matthew Shun} and Neil Chapman and Justin Davies and David Beckett and Amit Patel and Edroos, {Sadat Ali} and Nicholas Robinson and Iyer, {Sudha Ganesh} and Jeremy Sayer and Scott Biedermann and Sandeep Aggarwal and Jonathan Williams and Courtney Walsh and Ronald Victor and Radoslaw Owczuk and Jaguszewski, {Milosz J.} and Kroon, {A. A.} and Michiel Voskuil and Peter Blankestijn",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41440-024-01854-w",

language = "English",

volume = "47",

pages = "3467–3472",

journal = "Hypertension Research",

issn = "0916-9636",

publisher = "Springer Nature",

number = "12",

}

Bloch, MJ, Kirtane, AJ, Azizi, M, Mahfoud, F, Basile, J, Daemen, J, Saxena, M, Thackeray, L, McGuire, M, Claude, L, Schmieder, RE, Voskuil, M, Blankestijn, P 2024, '36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO', Hypertension Research, vol. 47, no. 12, pp. 3467–3472. https://doi.org/10.1038/s41440-024-01854-w

TY - JOUR

T1 - 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

AU - Bloch, Michael J.

AU - Kirtane, Ajay J.

AU - Azizi, Michel

AU - Mahfoud, Felix

AU - Basile, Jan

AU - Daemen, Joost

AU - Saxena, Manish

AU - Thackeray, Lisa

AU - McGuire, Maureen

AU - Claude, Lisa

AU - Schmieder, Roland E.

AU - Kröpil, Patric

AU - Stegbauer, Johannes

AU - Rump, Christian

AU - Uder, Michael

AU - Ott, Christian

AU - Lucic, Jelena

AU - Ewen, Sebastian

AU - Böhm, Michael

AU - Rommel, Karl Philipp

AU - Fengler, Karl

AU - Höllriegel, Robert

AU - Lurz, Philipp

AU - Elorz, Cristina

AU - Marshall, Andrew John

AU - Faris, Mohamad

AU - Gerber, Robert

AU - D’Souza, Richard

AU - Joseph, Anil

AU - Sharp, Andrew S.P.

AU - Howard, James

AU - Shin, Matthew Shun

AU - Chapman, Neil

AU - Davies, Justin

AU - Beckett, David

AU - Patel, Amit

AU - Edroos, Sadat Ali

AU - Robinson, Nicholas

AU - Iyer, Sudha Ganesh

AU - Sayer, Jeremy

AU - Biedermann, Scott

AU - Aggarwal, Sandeep

AU - Williams, Jonathan

AU - Walsh, Courtney

AU - Victor, Ronald

AU - Owczuk, Radoslaw

AU - Jaguszewski, Milosz J.

AU - Kroon, A. A.

AU - Voskuil, Michiel

AU - Blankestijn, Peter

PY - 2024/12

Y1 - 2024/12

N2 - Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)

AB - Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)

KW - blood pressure

KW - Hypertension

KW - renal denervation

KW - ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85204479483&partnerID=8YFLogxK

U2 - 10.1038/s41440-024-01854-w

DO - 10.1038/s41440-024-01854-w

M3 - Article

C2 - 39333663

AN - SCOPUS:85204479483

SN - 0916-9636

VL - 47

SP - 3467

EP - 3472

JO - Hypertension Research

JF - Hypertension Research

IS - 12

ER -

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this